With new $106M crossover round, Tenaya preps heart fail­ure pro­grams for the clin­ic — and maybe an IPO

Less than a year and a half since pulling in its last round of fund­ing, Tenaya Ther­a­peu­tics is back with a crossover round that could set it up for an IPO down the road.

Pri­vate and pub­lic in­vestors have now jumped aboard the Tenaya train to the tune of a $106 mil­lion Se­ries C, the com­pa­ny an­nounced Mon­day morn­ing, with the hopes of ad­vanc­ing its lead gene ther­a­py pro­gram for heart fail­ure in­to the clin­ic. Tenaya al­so aims to fund its oth­er heart fail­ure plat­forms, hav­ing made much progress in cel­lu­lar re­gen­er­a­tion and pre­ci­sion med­i­cine as well, CEO Faraz Ali told End­points News.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters